.svg)
The pace at which new oncology therapies reach patients depends on the speed and breadth of the research behind them. Commercial, clinical development, and outcomes teams need real-world evidence that is current enough to reflect today's care and comprehensive enough to power decisions across complex disease populations.
Precision360 was built to give research teams that capability. Introduced one year ago at the 2025 ASCO® Annual Meeting, Precision360 is the world’s highest-recency real-world dataset that operates with weekly data refreshes that span our oncology data foundation of more than 13 million patient records.
Leveraging AI curation, Precision360 provides high accuracy and reliability across hundreds of variables and 10+ tumor types, even in complex, unstructured datasets. We’ve already seen amazing impact grounded in the recency and depth of the data, and our pharmaceutical partners are using it to support active research and therapy development across their portfolios.
The Recency Problem in Oncology RWE
For most of the last decade, the conversation in oncology real-world evidence centered on depth and breadth, including the right variables, representative cohorts, validated mortality. Those questions still matter, but standards of care now move faster than refresh cycles can keep up with. New approvals, biomarker-driven labels, and competitive launches can reshape the treatment landscape inside a single quarter.
When the underlying RWE dataset refreshes quarterly, the industry default for years, teams are making decisions on data that is three to six months behind clinical practice.
This lag isn’t a data quality issue, but is a timing problem that exists because the curation infrastructure was built around human abstraction and what was reasonable for humans to sort through. With AI, we can think differently and optimize the use of data to power essential applications across the life sciences.
What's Different About Precision360
Precision360 was designed to remove that time constraint. The dataset is curated weekly by Cara™, ConcertAI's proprietary agentic healthcare AI platform, trained on millions of longitudinal patient records including structured and unstructured clinical data. The insights are purpose-built for the staging, biomarker, line-of-therapy, and progression fields that have always been the rate-limiting step in oncology curation.
For customers, that produces two compounding benefits:
- Recency. Precision360 refreshes weekly. The data customers work with today reflects what is happening in clinical practice now.
- Breadth of data. Because Cara is doing the curation, the practical ceiling on how many records can be processed shifts upward. More patients curated means more cohort options per study and more statistical power in populations where signal has historically been hardest to find.
Importantly, neither comes at the cost of depth. Precision360 maintains the same 120+ variables, longitudinal completeness, and deeply validated mortality customers rely on in Patient360.
What That Changes in Practice
Precision360 is being used by pharma companies across commercial, clinical development, and outcomes research workflows. Examples of this impact include:
Commercial. For brand teams supporting oncology launches, weekly data closes the loop between launch and response. Uptake, line-of-therapy positioning, payer dynamics, and competitive displacement become visible inside the quarter they happen in, giving teams room to course-correct rather than diagnose performance after the quarter has closed.
Clinical Trials. In oncology, eligibility windows can close within weeks. Weekly-refreshed matching pools identify patients while they are still candidates, translating into faster activation and a more reliable view of enrollment feasibility across a trial portfolio.
Outcomes Science. For rare or biomarker-defined populations, the historical trade-off has been stark: cohorts large enough for statistical power often lag the data, and current data is often too thin to support rigorous analysis. Weekly curation across a larger AI-curated foundation, combined with the genomic depth of linked Translational360 datasets, narrows that gap.
One Curation Engine, Across the Network
Precision360 is one expression of the underlying curation engine. The recently announced CancerLinQ® Suite enhancements, including TriaLinQ™ for AI-driven trial matching and PatientLinQ™ for real-world cohort comparisons, bring the same Cara-powered intelligence into the oncologist's workflow at the point of care.
Alongside new capabilities, the network powering this engine continues to grow. The CancerLinQ provider community now spans nearly 1,000 sites of care, with patient representation across all 50 states. We recently announced leading NCI cancer centers URochester Medicine Wilmot Cancer Institute and UCHealth/University of Colorado Anschutz Cancer Center joined the network.
The value is in the network, as every new site improves recency, breadth, and representativeness for every customer simultaneously, across Precision360, Patient360, Translational360, the ACT clinical trials platform, and the CancerLinQ Suite itself. This means that use cases that once felt years away are now operating capabilities.
Trust Is the Standard. Reality Is the Test.
In healthcare and life sciences, decisions do not happen in theory. They happen under pressure, scrutiny, and real-world constraints, where the cost of being wrong is high, and the cost of uncertainty is higher. That is the standard ConcertAI is built to meet: applied AI, validated for accuracy, refreshed weekly, and grounded in the longitudinal clinical depth oncology teams have always required.
Meet ConcertAI at ASCO 2026
If recency, accuracy, and clinical depth are converging in how your team evaluates real-world evidence partners, the 2026 ASCO® Annual Meeting is the right moment to see Precision360 in production.
Visit ConcertAI at booth #12131 in Chicago, May 29 – June 2, or book time with our team to walk through how AI curation is being applied across commercial, clinical development, outcomes research, and point-of-care decision support.
